Junshi Biosciences' Toripalimab Subcutaneous Formulation Clears NMPA Review for 12 Cancer Indications
Event summary
- Junshi Biosciences' NDA for toripalimab subcutaneous injection (JS001sc) across 12 cancer indications accepted by China's NMPA on March 9, 2026.
- JS001sc is the first domestically developed anti-PD-1 monoclonal antibody in subcutaneous formulation to reach marketing application stage.
- Phase 3 clinical trial (JS001sc-002-III-NSCLC) showed non-inferior exposure and comparable efficacy/safety vs. intravenous toripalimab.
- 12 indications cover all currently approved uses of toripalimab injection in mainland China.
The big picture
This approval represents a significant step in making cancer immunotherapy more convenient for patients, addressing the limitations of current intravenous administration methods. The subcutaneous formulation could become the new standard for PD-1 inhibitors in China's rapidly growing oncology market, where immunotherapy now covers nearly all treatment stages across multiple tumor types.
What we're watching
- Regulatory Timeline
- The pace at which NMPA completes its review and grants final approval for JS001sc.
- Market Adoption
- How quickly oncologists and patients transition from intravenous to subcutaneous toripalimab administration.
- Competitive Positioning
- Whether this formulation advantage helps Junshi maintain market share against other anti-PD-1 therapies in China.
Related topics